Radialis Inc. has developed the Radialis PET Imager, an organ-targeted positron emission tomography system that utilizes advanced silicon sensor technology to produce high-resolution images with low doses of radiotracer. This system addresses the challenge of accurately detecting early-stage cancers in high-risk populations, enabling more precise treatment planning and improved patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional whole-body PET scanners often lack the resolution and sensitivity needed to detect early-stage cancers or to precisely define the extent of tumors in specific organs. This limitation can lead to delayed diagnoses, inaccurate treatment planning, and unnecessary interventions.
Solution
Radialis Inc. offers the Radialis PET Imager, an organ-targeted positron emission tomography (PET) system designed to produce high-resolution images using low doses of radiotracer. By placing advanced silicon sensors close to the target organ, the system maximizes image resolution and contrast sensitivity, revealing clinically relevant details not visible in traditional PET scans. This targeted approach enables more accurate detection of early-stage cancers, improved treatment planning, and better monitoring of treatment response.
Target Audience
The primary target audience includes radiologists, oncologists, and nuclear medicine physicians seeking to improve early cancer detection, treatment planning, and monitoring of treatment response, as well as hospitals and imaging centers looking to enhance their diagnostic capabilities.
Features
- Organ-targeted design for high-resolution imaging of specific areas of concern
- Advanced silicon sensor technology for increased sensitivity and image clarity
- Low-dose radiotracer capability, suitable for frequent monitoring and high-risk populations
- Planar detectors that can be rotated and positioned for versatile imaging (seated, standing, or lying)
- Ability to resolve objects as small as 1.3mm
- Excellent contrast sensitivity for differentiating between adjacent areas of similar radiotracer uptake
- Small system footprint for easy integration into existing PET facilities
- FDA 510(k) cleared for commercialization in the United States